


WHO, WIPO, WTO WORKSHOP ON INNOVATION IN, AND ACCESS TO, COVID-19 TECHNOLOGIES

27 September 2021

Short briefing on access to therapeutics
to introduce panel discussion

Possible role of therapeutics



COMMON ACCESS AND DELIVERY CHALLENGES BY ASSET TYPE

Old repurposed Tx


- Known safety
- Widely available for other indications
- Competitive prices, closer to manufacturing cost
- Potential for temporary market instability

More recent repurposed Tx

- Available for other indications
- **Potential IP constraints**
- **Potential for high-prices/limited stocks without intervention**

Novel Tx

- High promise of efficacy
- Unknown safety
- **Potential IP constraints**
- **Potential for high-prices/limited stocks without intervention**



Small molecules

- Low to medium manufacturing complexity
- Medium to high supply capacity
- Generally adapted for delivery (oral, stability, exceptions)



Biologics


- Limited existing market (very limited in most low- and middle-income countries)
- Very high prices
- Complex manufacturing & regulatory pathways
- Delivery and use challenges

Three types of therapies in clinical trials ... with few already recommended for use

Others in earlier R&D stages

Repurposed drugs

Conclusive data expected for additional several off-patent products.
Several retargeted products (tocilizumab, sarilumab) WHO-recommended.
Others under consideration.



Novel antiviral drugs

3 oral antivirals now in clinic with manufacturers stating goals to have data by end H2

Monoclonal antibodies

mAbs (monotherapies and combinations) retaining activity against variants progressing through clinic, testing non-IV formulations. Casirivimab/imdevimab: recommendation by WHO Sept 24. Others data expected H2.

ACT-A'S GOAL : MEANINGFUL, GLOBAL, EQUITABLE ACCESS

Ensure investments prevent and close equity gaps and mitigate risks




Equity of access

ACT-A partners look for access plans that provide meaningful, global, equitable access in all low- and middle-income countries




Access for everyone

We refer to all low-income countries, lower middle-income countries *and* upper middle-income countries



Narrow availability gap

Narrow the gap between originator product availability in HICs & product in low- and middle-income countries (originator/generic)




Short- and long-term

Access plan should address both short-term and more sustained access with sufficient, affordable volumes to meet demand in low- and middle-income countries

ACTaccelerator

ACCESS TO COVID-19 TOOLS



#UnitedAgainstCoronavirus
#StrongerTogether | #GlobalResponse | #GlobalGoalUnite